Malignant Lymphoma - Lymphoplasmacytic, Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma
Conditions
Brief summary
Cell- and antibody-based therapies, including chimeric antigen receptor T-cell (CAR-T) therapy and bispecific antibodies, represent significant advances in the treatment of hematologic malignancies. These therapies optimise the patient's immune system to target and eliminate malignant cells, achieving profound and durable responses in patients where conventional treatment approaches have failed. However, their mechanism of action-through profound immune activation-introduces a challenging toxicity profile, including cytokine release syndrome and immune effector cell-induced neurotoxicity. Emerging evidence suggests that neurotoxicity associated with these therapies may extend beyond acute symptoms to include persistent cognitive impairments. Such impairments can manifest deficits in memory, attention, executive functioning, and processing speed, potentially compromising patients' quality of life, ability to manage daily activities and return to work. The COGNITOX project explores the occurrence, clinical manifestations, and impact on quality of life of neuro-psychologically assessed and patient-reported cognitive impairment. The project's data set is generated through standardized neuropsychological tests (recommended by the International Cognition and Cancer) and validated patient reported outcome measures, to evaluate multiple cognitive domains. The project is developed in close collaboration between the Department of Haematology, Aarhus University Hospital and the Unit for Psychooncology and Health Psychology (EPoS), Department of Psychology and Behavioural Sciences, Aarhus University. The current literature on cognitive impairment secondary to cell- and antibody-based therapies is limited, and none of the studies reported so far were conducted within a Danish healthcare context. Understanding the prevalence, severity, and functional impact of cognitive impairments in this patient population is critical. These insights will inform clinical practice, guide patient counseling, and support the development of targeted interventions aimed at mitigating cognitive decline. By generating robust data, this project seeks to improve the knowledge within the field and lay the foundation for an intervention study addressing the needs of patients undergoing these advanced immunotherapies.
Interventions
OTHERNeuropsychological tests and patient reported outcome
Cognitive assessments will be conducted by a clinical nurse specialist and/or a project nurse working at the department. Both are trained by expert neuropsychologists (AA and LW). The cognitive assessments will be conducted at baseline, i.e. prior to one of the protocolled cell- or antibody-based immunotherapies, and at 3-, 6-, 12-, 24-, and 36-month after treatment in concomitance with an appointment at the outpatient clinic for planned control visits. The cognitive assessment will approximately take 1-1½ hour. The results of the tests will not be immediately available for the individual patient, because the analysis will be performed on a later set of pooled data. However, patients will be offered a summarized version of the test results at 1-year follow-up. In relation to the neurocognitive assessment, patients will also be invited to complete electronic questionnaires.
Sponsors
Aarhus University Hospital
Study design
Observational model
OTHER
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients must be ≥ 18 years old * Able to speak and read Danish * Provide informed consent
Exclusion criteria
* CNS-involvement by the haematological malignancy * Cognitive impairment due to pre-existing psychiatric or neurological conditions
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Cancer related cognitive impairment (CRCI) | Day 0, month 3, month 6, month 12, month 24, month 36 | The primary endpoint of the study is the occurrence, of cancer related cognitive impairment (CRCI) in patients treated with either chimeric antigen receptor T-cell therapy (CAR-T) or bispecific antibodies (BsAbs) as compared to high dose chemotherapy with autologous haematopoietic stem cell transplantation (AutoHSCT). Clinical manifestations and severity of CRCI will also be reported as descriptive co-primary endpoints. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall and progression-free survival | 3 years | Overall and progression-free survival |
| Health related quality of life (HM-PRO score) | 3 years | The HM-PRO has 24 items in Part A and 18 items in Part B. Each question has three response options: Part A Not at all (score = 0) A little (1) A lot (2) Not applicable Part B Not at all (score = 0) Mild (1) Severe (2) The score range for Part A is 0-48 and for Part B is 0-36. The higher the total score, the greater the effect on a patient's quality of life. The items in the HM-PRO are divided into four categories (domains): Physical Behaviour (the first 7 items, maximum score of 14) Social Well-being (the second 3 items, maximum score of 6) Emotional Behaviour (the third 11 items, maximum score of 22) Eating and Drinking (the last 3 items, maximum score of 6) HM-PRO Part A score is reported as a single total score HM-PRO A-total, score range 0-48 The HM-PRO Part A score is also reported as four separate scores: HM-PRO Physical, score range 0-14 HM-PRO Social, score range 0-6 HM-PRO Emotional, score range 0-22 HM-PRO Eating/Drinking, score range 0-6 HM-PRO B-total (score range 0-36) |
| Return to work (RTW) | 3 years | Return to work/occupational status Day 0 the following data is collected: 1. Self-employed 2. Employee 3. Working full time 4. Working part time (hours/week) 5. Unemployed 6. On sick leave 7. Early retirement 8. Pensioner 9. Dismissed 10. Disability or anticipatory pensioner 11. Enrolled in education 1. Continue studies during the treatment 2. Pausing studies during the treatment 3. Dropped out of study/education 12. Other Data collected at 6-, 12-, 24-, 36-month follow-up: * Still on sick leave * Dismissed * Gradually increasing hours/week. Aiming at return to full time/part time * Worked full time or part time at baseline, changed to: Working part time or part time, but less hours/week than before • Changes in job description (yes/no) if yes: New less responsible job description Other changes in job description * Enrolled in education Continue/pausing studies during the cancer treatment and follow-up Completed education Dropped out of study/education * Retired * Other |
Countries
Denmark
Outcome results
None listed